Biotechnology

The world's top virologists now have a permanent home at the University of South Florida, forging a new global nexus for pandemic preparedness.

A massive investment in Kankakee promises hundreds of jobs and a vital increase in life-saving plasma therapies for patients with rare diseases.

A new, highly selective drug for Duchenne muscular dystrophy shows potential to be safer and more effective, targeting both muscle and heart decline.

A landmark European approval for Elfabrio allows stable Fabry disease patients to switch to monthly infusions, promising greater freedom and lower healthcare strain.

As electroCore preps its 2025 financial report, all eyes are on its product growth, the new Quell device, and its path to profitability in the booming bioelectronic market.

As Capricor prepares its Q4 earnings call, all eyes are on its DMD drug Deramiocel's FDA path, financial health, and next-gen exosome technology.

Medicus Pharma's microneedle patch for basal cell carcinoma clears nearly three-quarters of lesions, offering a potential non-surgical alternative to the scalpel.

With new data on CUE-401, a novel therapy inspired by Nobel-winning science, Cue Biopharma makes a high-stakes play to redefine autoimmune treatment.

Founded by Emma Heming Willis, Make Time Wellness unveils three new products, tapping into a booming market with science-backed solutions for women's brain health.

A year after rebranding from FibroGen, Kyntra Bio's first full-year report will test if its lean strategy can fuel its ambitious oncology pipeline.

With one trial halted and another beginning, the company focuses its cash and hopes on BBI-940, a novel drug targeting a fundamental driver of cancer.

A new AI-designed drug shows promise in selectively burning fat while preserving muscle, with a potential twice-yearly dosing schedule for obesity.

UK's Abselion opens a US base in Cambridge, MA, aiming to disrupt biologics R&D with its rapid Amperia protein quantification system.

IDEAYA Biosciences begins a key trial for its targeted therapy IDE892, aiming to conquer hard-to-treat tumors and pivoting to focus on its proprietary assets.

With its runway extended by insiders, the biotech firm bets on its promising glioblastoma drug and an unconventional strategy of crypto and acquisitions.

Beijing is pouring trillions into AI, 6G, and biomanufacturing to dominate the next tech era, offering Europe partnership amidst rising competition.

Early access programs for a rare blindness therapy in France, Israel, and the US offer hope to patients and provide a crucial financial lifeline for the company.

A new trial in China tests a dual-action antibody for esophageal cancer, a top killer. The therapy aims to unleash a two-pronged immune attack on tumors.

Amid rising avian flu concerns, Canada secures millions of next-gen cell-based vaccines, upgrading its pandemic response arsenal for faster protection.

French pharma giant Servier acquires Day One Biopharmaceuticals, gaining a breakthrough pediatric cancer drug and signaling a major push into rare oncology.